on INTRASENSE (EPA:ALINS)
Intrasense: Strategic Transition and Ambitions in Artificial Intelligence
Intrasense, a French specialist in medical imaging solutions enhanced with artificial intelligence, announced a 59.3% drop in revenue for the first half of 2026, reaching €646,000. This decline is attributed to delays in the renewal of maintenance contracts and license orders. All of the business was generated within the Myrian® division, which is currently being sold.
This divestment will allow Intrasense to focus on its DUOnco™ artificial intelligence solutions, particularly those designed for oncology. DUOnco™ Pancreas, a solution developed with Guerbet, has obtained certification in Japan. DUOnco™ Unity, in its final stages of development, aims for CE marking by the third quarter of 2026.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTRASENSE news